Goldman Sachs’s AstraZeneca AZN Stock Holding History

Goldman Sachs’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58.8M	Buy	298,000 +260,500	+695%	+$50.2M	0.01%	1448
2025 Q4	$6.89M	Sell	37,500 -48,000	-56%	-$8.42M	﹤0.01%	3449
2025 Q3	$13.1M	Buy	85,500 +48,000	+128%	+$7.26M	﹤0.01%	2697
2025 Q2	$5.24M	Sell	37,500 -893,650	-96%	-$125M	﹤0.01%	3364
2025 Q1	$137M	Buy	931,150 +893,650	+2,383%	+$129M	0.02%	650
2024 Q4	$4.91M	Hold	37,500	–	–	﹤0.01%	3476
2024 Q3	$5.84M	Buy	+37,500	New	+$6.05M	﹤0.01%	3211
2024 Q2	–	Sell	-12,500	Closed	-$1.69M	–	5650
2024 Q1	$1.69M	Buy	+12,500	New	+$1.66M	﹤0.01%	3981
2022 Q4	–	Sell	-37,150	Closed	-$4.08M	–	5978
2022 Q3	$4.08M	Buy	+37,150	New	+$4.71M	﹤0.01%	3312
2022 Q1	–	Sell	-25,800	Closed	-$3.01M	–	6562
2021 Q4	$3.01M	Buy	+25,800	New	+$3.04M	﹤0.01%	3881
2021 Q2	–	Sell	-21,250	Closed	-$2.11M	–	6190
2021 Q1	$2.11M	Buy	+21,250	New	+$2.14M	﹤0.01%	3920
2020 Q4	–	Sell	-12,550	Closed	-$1.38M	–	5478
2020 Q3	$1.38M	Sell	12,550 -84,250	-87%	-$9.37M	﹤0.01%	3850
2020 Q2	$10.2M	Buy	96,800 +72,350	+296%	+$7.47M	﹤0.01%	2255
2020 Q1	$2.18M	Sell	24,450 -72,200	-75%	-$6.8M	﹤0.01%	3238
2019 Q4	$9.64M	Sell	96,650 -500	-0.5%	-$47.1K	﹤0.01%	2456
2019 Q3	$8.66M	Buy	97,150 +81,900	+537%	+$7.1M	﹤0.01%	2430
2019 Q2	$1.26M	Buy	+15,250	New	+$1.2M	﹤0.01%	3836
2019 Q1	–	Sell	-35,200	Closed	-$2.67M	–	5111
2018 Q4	$2.67M	Buy	35,200 +35,000	+17,500%	+$2.73M	﹤0.01%	3346
2018 Q3	$16K	Sell	200 -72,150	-100%	-$5.46M	﹤0.01%	5431
2018 Q2	$5.08M	Hold	72,350	–	–	﹤0.01%	2953
2018 Q1	$5.06M	Buy	72,350 +54,950	+316%	+$3.81M	﹤0.01%	2876
2017 Q4	$1.21M	Sell	17,400 -12,700	-42%	-$856K	﹤0.01%	4186
2017 Q3	$2.04M	Sell	30,100 -114,000	-79%	-$7.2M	﹤0.01%	3970
2017 Q2	$9.82M	Buy	144,100 +109,050	+311%	+$7.12M	﹤0.01%	2519
2017 Q1	$2.18M	Sell	35,050 -8,700	-20%	-$506K	﹤0.01%	3663
2016 Q4	$2.39M	Sell	43,750 -128,400	-75%	-$7.29M	﹤0.01%	3686
2016 Q3	$11.3M	Buy	172,150 +69,600	+68%	+$4.55M	﹤0.01%	2351
2016 Q2	$6.19M	Buy	102,550 +91,650	+841%	+$5.32M	﹤0.01%	2689
2016 Q1	$614K	Sell	10,900 -54,150	-83%	-$3.25M	﹤0.01%	4543
2015 Q4	$4.42M	Sell	65,050 -32,950	-34%	-$2.16M	﹤0.01%	2941
2015 Q3	$6.24M	Sell	98,000 -86,500	-47%	-$5.69M	﹤0.01%	2680
2015 Q2	$11.8M	Buy	184,500 +164,800	+837%	+$11.3M	﹤0.01%	2201
2015 Q1	$1.35M	Sell	19,700 -447,600	-96%	-$31.1M	﹤0.01%	4181
2014 Q4	$32.9M	Sell	467,300 -305,400	-40%	-$21.9M	0.01%	1448
2014 Q3	$55.2M	Sell	772,700 -940,400	-55%	-$68.8M	0.02%	997
2014 Q2	$127M	Buy	1,713,100 +161,900	+10%	+$11.7M	0.04%	553
2014 Q1	$101M	Sell	1,551,200 -392,800	-20%	-$25.4M	0.03%	618
2013 Q4	$115M	Buy	1,944,000 +1,033,200	+113%	+$56.1M	0.04%	569
2013 Q3	$47.3M	Buy	910,800 +628,400	+223%	+$31.6M	0.02%	998
2013 Q2	$13.4M	Buy	+282,400	New	+$14.4M	0.01%	1839

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Goldman Sachs's AZN Position: Q1 2026 in Review

Goldman Sachs increased its AstraZeneca (AZN) stake by 47% in Q1 2026, buying an estimated $656M and bringing the position to 10,605,842 shares worth $2.09B. The position accounts for 0.24% of the portfolio, ranked #63.

Goldman Sachs first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Goldman Sachs held 10,605,842 shares of AstraZeneca worth $2.09B as of Q1 2026.
Goldman Sachs bought 3,400,181 AstraZeneca shares in Q1 2026, an estimated $656M.
AstraZeneca made up 0.24% of Goldman Sachs's portfolio in Q1 2026, its #63 holding.
Goldman Sachs first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.